title: Open to debate. The motion: PDE5 inhibitors are a promising therapy for benign prostatic hyperplasia.
authors.affiliation: Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. k-mcvary@northwestern.edu
authors.forename: Kevin
authors.initials: K
authors.lastname: McVary
authors.forename: Andreas
authors.initials: A
authors.lastname: Tubaro
authors.forename: Cosimo
authors.initials: C
authors.lastname: De Nunzio
mesh_terms: D003363:Cost Control; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors